FinQuota.com
Home
News
Screener
Backtests
Tools
Compare Stocks
Dividend Calculator
Options Calculator
NYSE Holidays
NASDAQ Holidays
Earnings Calendar
Widgets
Filter
Dividend Stocks
US Dividend Stocks
Monthly Dividend Stocks
Annual Dividend Stocks
Quarterly Dividend Stocks
Semi-Annual Dividend Stocks
Best Penny Stocks
Undervalued Stocks
New Stocks
Uptrend Stocks
Uptrend Penny Stocks
Blue Chip
Blue Chip Stocks With High Dividends
Blue Chip Under $10
Blue Chip Under $20
Blue Chip Under $50
Undervalued Blue Chip Stocks
By Cap
Best Small Cap
Best Micro Cap
Best Mid Cap
Best Large Cap
By Sector
Oil Stocks
Energy Stocks
Technology Stocks
AI Stocks
Pharma Stocks
Financial Stocks
By Price
Under $200
Under $100
Under $50
Under $20
Under $10
Under $5
Under $1
By 52 Week Range
Best 52 Week Low
Best 52 Week Nasdaq Low
Best 52 Week NYSE Low
Best 52 Week Low Penny
Best 52 Week Low Blue Chip
Best 52 Week High
Best 52 Week Nasdaq High
Best 52 Week NYSE High
Best 52 Week High Penny
By Exchange
Best Nasdaq Stocks
Best NYSE Stocks
By Insider Activity
Insider Buying
Insider Selling
By Indicator
MACD Crossed Above Signal Line
MACD Crossed Above Zero
RSI Above 90
RSI Above 80
RSI Above 70
RSI Above 50
RSI Below 50
RSI Below 30
RSI Below 20
RSI Below 10
By P/E Ratio
Tech Stocks with Low PE
PE Ratio Less Than 1
PE Ratio Less Than 10
PE Ratio Less Than 15
US stocks With Low PE
Low PE & High Dividends
Low PE & High EPS
Large Cap & Lowest PE
Learning
Books
Trading Platforms
Blog
Forum
Auto (Default)
Light mode
Dark
Sign In
Sign Up
FinQuota.com
Home
Account
Sign In
Sign Up
News
Screener
Backtests
Tools
Compare Stocks
Dividend Calculator
Options Calculator
NYSE Holidays
NASDAQ Holidays
Earnings Calendar
Widgets
Filter
Dividend Stocks
US Dividend Stocks
Monthly Dividend Stocks
Annual Dividend Stocks
Quarterly Dividend Stocks
Semi-Annual Dividend Stocks
Best Penny Stocks
Undervalued Stocks
New Stocks
Uptrend Stocks
Uptrend Penny Stocks
Blue Chip
Blue Chip Stocks With High Dividends
Blue Chip Under $10
Blue Chip Under $20
Blue Chip Under $50
Undervalued Blue Chip Stocks
By Cap
Best Small Cap
Best Micro Cap
Best Mid Cap
Best Large Cap
By Sector
Oil Stocks
Energy Stocks
Technology Stocks
AI Stocks
Pharma Stocks
Financial Stocks
By Price
Under $200
Under $100
Under $50
Under $20
Under $10
Under $5
Under $1
By 52 Week Range
Best 52 Week Low
Best 52 Week Nasdaq Low
Best 52 Week NYSE Low
Best 52 Week Low Penny
Best 52 Week Low Blue Chip
UBest 52 Week High
Best 52 Week Nasdaq High
Best 52 Week NYSE High
Best 52 Week High Penny
By Exchange
Nasdaq Stocks
NYSE Stocks
By Insider Activity
Insider Buying
Insider Selling
By Indicator
MACD Crossed Above Signal Line
MACD Crossed Above Zero
RSI Above 90
RSI Above 80
RSI Above 70
RSI Above 50
RSI Below 50
RSI Below 30
RSI Below 20
RSI Below 10
By P/E Ratio
Tech Stocks with Low PE
PE Ratio Less Than 1
PE Ratio Less Than 10
PE Ratio Less Than 15
US stocks With Low PE
Low PE & High Dividends
Low PE & High EPS
Large Cap & Lowest PE
Learning
Books
Trading Platforms
Blog
Forum
Search Ticker
Home
MTVA
MTVA News
Latest METAVIA INC (MTVA) News on February 23, 2025
MTVA
Zacks Small Cap Research
a month ago
Zacks Small Cap Research 2024 Initiations and Best Ideas for 2025
MTVA
PR Newswire
a month ago
MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference
MTVA
Zacks Small Cap Research
2 months ago
MTVA: Compelling Data for DA-1241 in Phase 2a MASH Trial…
MTVA
PR Newswire
2 months ago
MetaVia to Participate in the 9th Annual MASH-TAG 2025 Conference After Releasing Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH
MTVA
PR Newswire
2 months ago
MetaVia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH
MTVA
ACCESSWIRE
3 months ago
Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing
MTVA
GlobeNewswire
3 months ago
Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now
MTVA
Zacks Small Cap Research
3 months ago
MTVA: NeuroBo Becomes MetaVia; Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024…
MTVA
PR Newswire
3 months ago
MetaVia to Present at the Emerging Growth Conference in December
Share on Social Networks: